SCHEMBL14697153

SCHEMBL14697153

C[Si](C)(C)CCOCn1ccc2c1ncc1c(=O)ncn(C3CCCCC3)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
AURKA O14965 1/20 0.32
JAK2 O60674 1/20 0.32
PRKCA P17252 1/20 0.32
JAK1 P23458 1/20 0.32
KDR P35968 1/20 0.32
JAK3 P52333 1/20 0.32
LMNA P02545 4/20 0.32
NPSR1 Q6W5P4 2/20 0.32
THRB P10828 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
DGAT1 O75907 1/20 0.31
GRM1 Q13255 1/20 0.31
CNOT7 Q9UIV1 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15944917 0.89 BRD4 (0.32) BRD4CREBBPDGAT1
SCHEMBL15944797 0.89 BRD4 (0.32) BRD4CREBBPDGAT1
SCHEMBL15944686 0.89 BRD4 (0.32) BRD4CREBBP
SCHEMBL17329152 0.88 BRD4 (0.32) BRD4CREBBPDGAT1
SCHEMBL14697426 0.88 JAK2 (0.34) KDM4EKMT2ABRD4CREBBPJAK2
SCHEMBL15944909 0.86 BRD4 (0.31) BRD4CREBBP
SCHEMBL15944658 0.85 DUT (0.36) BRD4CREBBPDGAT1
SCHEMBL3321628 0.81 JAK1 (0.33) BRD4CREBBPJAK2JAK1JAK3
SCHEMBL13398127 0.81 JAK1 (0.33) BRD4CREBBPJAK2JAK1JAK3
SCHEMBL3314301 0.81 BRD4 (0.34) BRD4CREBBPALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2955181-B1 TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR NISSAN CHEMICAL CORP (JP) 2019-10-30 EP disclosed
EP-2955181-B1 TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR NISSAN CHEMICAL CORP (JP) 2019-10-30 EP disclosed
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 US disclosed
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 US disclosed
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 US disclosed
EP-3112370-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS Nissan Chemical Industries, Ltd. (JP) 2017-01-04 EP disclosed
EP-3112370-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS Nissan Chemical Industries, Ltd. (JP) 2017-01-04 EP disclosed
US-9475813-B2 Tricyclic pyrrolopyridine compound, and JAK inhibitor NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-25 US disclosed
US-9475813-B2 Tricyclic pyrrolopyridine compound, and JAK inhibitor NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-25 US disclosed
US-9475813-B2 Tricyclic pyrrolopyridine compound, and JAK inhibitor NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-25 US disclosed
US-9216999-B2 Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-12-22 US disclosed
US-9216999-B2 Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-12-22 US disclosed
US-9216999-B2 Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-12-22 US disclosed
EP-2955181-A1 TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR Nissan Chemical Industries, Ltd. (JP) 2015-12-16 EP disclosed
EP-2955181-A1 TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR Nissan Chemical Industries, Ltd. (JP) 2015-12-16 EP disclosed
WO-2014123167-A1 TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR 日産化学工業株式会社 (JP) 2014-08-14 WO disclosed
US-20140200344-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-07-17 US disclosed
US-20140200344-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-07-17 US disclosed
EP-2742049-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS Nissan Chemical Industries, Ltd. (JP) 2014-06-18 EP disclosed
WO-2013024895-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200344-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS JAK2, JAK1, JAK3 KDM4E 1930/4885KMT2A 449/4885BRD4 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.